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Abstract
Stem cell transplantation holds great promise for the treatment of myocardial infarction injury. We recently described the
embryonicstemcell-derivedcardiacprogenitorcells(CPCs)capableofdifferentiatingintocardiomyocytes,vascularendothelium,
and smooth muscle. In this study, we hypothesized that transplanted CPCs will preserve function of the infarcted heart by
participating in both muscle replacement and neovascularization. Differentiated CPCs formed functional electromechanical
junctions with cardiomyocytes in vitro and conducted action potentials over cm-scale distances. When transplanted into
infarctedmousehearts,CPCs engraftedlong-termintheinfarct zone andsurroundingmyocardiumwithout causingteratomas or
arrhythmias. The grafted cells differentiated into cross-striated cardiomyocytes forming gap junctions with the host cells, while
also contributing to neovascularization. Serial echocardiography and pressure-volume catheterization demonstrated attenuated
ventricular dilatation and preserved left ventricular fractional shortening, systolic and diastolic function. Our results demonstrate
that CPCs can engraft, differentiate, and preserve the functional output of the infarcted heart.
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Introduction
Cardiomyocyte loss as a result of myocardial infarction (MI)
injury is considered irreversible with the heart lacking sufficient
capacity for self-regeneration. Cell-based cardiac therapies are
proposed as an attractive therapeutic alternative to reverse
cardiomyocyte loss, repair the injured myocardium and ultimately
prevent heart failure. To date, a variety of cell sources, both of
adult and embryonic origin, have been investigated for use in heart
repair with mixed outcomes [1,2]. The use of adult cells is
attractive because of their immunocompatible nature, ease of
isolation, restricted differentiation potential, and capacity to
proliferate rapidly. However, inadequate potential for cardiac
differentiation or integration with host cells, limits the benefit of
these cells mainly to their paracrine action. On the other hand,
embryonic stem cells (ESCs) are able to differentiate into relatively
large numbers of early stage cardiomyocytes that functionally
integrate with host heart cells [3,4,5]. While ESC-derived
cardiomyocytes have been successfully applied for the treatment
of myocardial infarction in animal models [6,7,8,9], their clinical
application is currently hampered by their neoplastic and
immunogenic potential [10].
We and others have recently described the identification,
isolation, and characterization of the novel mouse ESC-derived
cardiac progenitor cells (CPCs) on the basis of Brachyury/Flk1
[11], Isl1/Flk1/Nkx2-5 [12], cKit/Nkx2-5 [13], or Nkx2-5 [14]
expression. These cells represent a promising source for heart
repair as they have the restricted capacity to differentiate into
cardiac muscle, smooth muscle, and vascular endothelium
[11,12,13,14]. In this study we hypothesized that mouse ESC-
derived CPCs will exert functional improvement after myocar-
dial infarction primarily through their multipotential differen-
tiation capacity as well as through the formation of stable and
integrated grafts within the host myocardium. We found that
when co-cultured with neonatal rat ventricular cardiomyocytes
(NRMVs), the CPCs differentiated into cardiomyocytes, formed
gap junctions with the rat cells, and supported electrical
propagation over a centimeter-scale distance. Temporal assess-
ment performed as long as one month after injection into the
infarcted region of the murine myocardium, demonstrated that
the CPCs engrafted and differentiated into cardiomyocytes, as
well as contributed to neovascularization in the infarcted region.
The differentiated cardiomyocytes also formed gap junctions
with the host myocardium. The animals that received the CPCs
demonstrated significantly improved cardiac function as assess-
ed by echocardiography and pressure/volume (PV) loop
analysis. No teratoma formation was observed following cell
transplantation.
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Isolation and in vitro characterization of mouse ESC-
derived CPCs
The mouse ESC lines D3 [15] and Rosa26 [16] were stably
transfected with DNA constructs allowing the expression of the
green fluorescent protein (GFP) under the control of the mouse
cardiac specific enhancer element of the Nkx2-5 transcription
factor as previously described [14]. Following isolation of 50
colonies (clonal) for each cell line, stably transfected clones were
identified and further used based on their capacity to express GFP
selectively in the spontaneously contracting cardiomyocyte cell
clusters. Mouse ESCs were induced to differentiate in suspension
forming aggregates termed embryoid bodies (EBs) and initial
detection of GFP coincided with initiation of Nkx2-5 expression on
differentiation day 5 (Figs. 1a, b).
Temporal quantitative RT-PCR analysis performed on differ-
entiating ESCs indicated a time period (days 5–6) during which
the CPCs were present but not yet committed into specific cell
lineages (Fig. 1g). Prior to initiation of Nkx2-5 expression,
coinciding with cardiac progenitor induction, the detection of
Brachyury transcripts (day 4) indicated the formation of nascent
mesoderm. By day 7, the CPCs underwent differentiation-
commitment into cardiac cell lineages including cardiomyocytes
as indicated by the initiation of Mhc6 expression along with the
detection of spontaneously contracting cell clusters.
The initial number and percentage of GFP
(+) CPCs decreased
temporally between days 5 and 10 (Fig. 1h). This observation,
which has been previously reported [13], may be a result of
proliferation of other cell types, epigenetic silencing of the specific
Nkx2-5 enhancer element used in this set of experiments, and/or
differentiation towards the vascular and smooth muscle endothe-
lium cell lineages which downregulate Nkx2-5.
To assay the differentiation capacity of the CPCs, following
isolation of the GFP
(+) progenitor population, the cells were
reaggregated and the cell clusters were induced to differentiate for
7–30 days. Several foci of GFP
(+) spontaneously contracting
cardiomyocytes (a-Actinin expression) were detected in culture
(Figs. 1c, d). The multi differentiation potential of the CPCs was
determined by demonstrating cell specific expression of cardiac a-
Actinin, endothelial Von-Willebrand factor, and smooth muscle
actin in the differentiating clusters (Figs. 1e, f). This was also
confirmed by the RT-PCR analysis (previously demonstrated
[14]). No colonies of undifferentiated ESCs were detected as
confirmed by the absence of Pou5f1 and Nanog expression.
Determination of the electrocoupling capacity of CPCs
The potential of CPC derived cardiomyocytes to form
functional gap junctions was determined by utilizing a previously
described in vitro NRVM co-culture assay [17,18] which allows the
observation of action potential propagation by the means of
optical mapping over a macroscopic (3 cm2) culture area [18]. In
particular, the CPCs were selectively seeded at high density in the
central region of pre-masked coverslips with the NRVMs
surrounding them (Fig. 2a). The co-cultures exhibited distinct
border between the CPCs and the NRVMs as assayed by GFP and
a-Actinin expression (Figs. 2a, b). Immunostaining for cardio-
myocyte, smooth muscle and endothelial markers after 14 days of
co-culture demonstrated that the majority of the CPCs differen-
tiated into cardiomyocytes (Fig. 2c) with limited smooth muscle or
endothelial cell differentiation (data not shown). On the other
hand, CPCs plated at low density in the central region of the
coverslips formed few patches of cardiomyocytes with the majority
of cells differentiating into smooth muscle cells (Fig. S1). Gap
junctions indicated by punctuate Connexin 43 localization at the
site of cell-cell contacts were detected in the differentiated
cardiomyocytes (Fig. 2d). However, unlike the NRVMs that
expressed Connexin 43 in relatively long plaques at the sites of cell
contacts, the CPC-derived cardiomyocytes expressed Connexin 43
sporadically and irregularly.
Optical mapping in all co-cultures revealed spontaneous
electrical activity at a relatively low rate (1.260.3 Hz) that
originated in the CPC islands, suggesting the existence of
pacemaking cells amongst the CPC-differentiated cardiomyocytes.
Consistent with positive staining for Connexin 43, both sponta-
neous and pacing-induced action potentials (2 Hz rate) within the
CPC island propagated outwards into the surrounding NRVM
area (Fig. 2e). Action potentials also propagated into the CPC
island when initiated from the surrounding NRVM area (data not
shown). The apparent velocity of electrical propagation inside the
CPC island was significantly lower as compared to that of the
surrounding NRVMs (1.660.2 vs. 16.761.5 cm/s) and dependent
on the efficiency of CPC differentiation into cardiomyocytes.
Specifically, lower numbers of sparsely distributed cardiomyocytes
within the central island yielded significantly lower velocity of
propagation (0.460.1 cm/s, Fig. S1g).
CPC injection in the mouse infracted myocardium
The potential of CPCs to treat myocardial infarction injury was
assessed by evaluating their ability to form stable grafts in the host
myocardium, differentiate into lineage-committed cells, form in
vivo gap junctions, and ultimately improve the functional output of
the injured hearts. To determine the extent of injury and scar
tissue formation in the infarcted hearts, we performed Mason’s
trichrome staining on thin heart sections that allowed us to
distinguish healthy muscle tissue (red) from scar tissue (blue)
(Fig. 3). The control group that underwent sham surgery
displayed only minor scarring which could be attributed to injury
sustained during the saline injections (Figs. 3a, b). The hearts
that underwent LAD ligation and received only saline injections
sustained massive infarcts that encompassed almost the entire left
ventricle (including apex) and exhibited thin scarred walls and
extensive remodeling (Figs. 3c, d). In contrast, the animals that
underwent LAD ligations and received CPCs displayed smaller
zones of scar tissue formation with decreased cardiac remodeling
(Figs 3e–h). While a few hearts displayed minor tissue scarring
(Figs. 3e, f) similar to that observed in the sham hearts, others
displayed a certain degree of wall thinning and remodeling
(Figs. 3g, h). In this case, however, the scar was localized only
around the ligation site.
To assess the engraftment potential and distribution of the
transplanted cells irrespective of their lineage differentiation
phenotype within the myocardium we compared parallel serial
tissue cross-sections pre-treated either with Mason’s trichrome
stain or anti b-Galactosidase, which is constitutively expressed in the
Rosa26-derived CPCs (Figs. 3i, l). b-Gal
(+) cells were detected
within the infarcted region in an area comprising a thin muscle
band underneath the scar tissue (Fig. 3i), borders between the scar
tissue and healthy muscle (Figs. 3j, k), as well as within the
healthy muscle in the vicinity (Fig. 3l) but not remote (not shown)
from the scar. These results suggested that the transplanted cells
successfully engrafted at all three injection areas including the
center of the infarct.
Anti b-Galactosidase-specific staining was also used in order to
determine the survival rate of the transplanted cells one month
post intramyocardial delivery. bGal
(+) cells was detected and
summed in multiple sections both within and in the surrounding
area of the myocardial infarction region. The survival rate was
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11536Figure 1. Derivation and in vitro characterization of mouse ESC-derived CPCs. ESCs were induced to differentiate through 3D
aggregation and embryoid body formation. Clusters of CPCs, located within the embryoid body, expressed GFP under the control of the Nkx2-5
enhancer element (a–b). GFP
(+) CPCs isolated by FACS sorting differentiated exclusively into cardiomyocytes (a-Actinin) while retaining GFP
expression (c–d). The CPCs differentiated in vitro into cardiomyocytes (a-Actinin), smooth muscle (Smooth muscle actin), and endothelial cells
(Von Willebrand factor) (e–f). Temporal quantitative RT-PCR analysis for the nascent mesoderm marker Brachyury, the cardiac progenitor marker
Nkx2-5, and a cardiomyocyte marker Mhc6 (g). The percentage of GFP
(+) CPCs was determined temporally following induction of mouse ESC
differentiation (h).
doi:10.1371/journal.pone.0011536.g001
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PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11536Figure 2. Structural and functional assessment of a NRVM monolayer with a central island comprised of differentiated CPCs. A
GFP
(+) CPC island (green) within the cardiac network (red) (a–b). Composite image and separate fluorescence channels showing the border between
NRVMs and CPCs (c). Note that significant number of GFP positive cells are also a-Actinin positive (cardiomyocytes). Composite image and separate
channels showing the Connexin 43 staining within the CPC island. While NRVMs were connected via relatively long Connexin 43
(+) gap-junction
plaques (data not shown), the gap-junctions in CPC differentiated cardiomyocytes appear small and irregular (d). Electrical propagation initiated
inside the CPC island propagated into the surrounding cardiac network (e). Individual hexagonal frames denote 19.5 mm diameter recording area
with membrane voltage snapshots shown at given times. Electrical stimulus (pulse sign) was applied in the center of the CPC island at time 0 ms.
Membrane voltage is color coded from rest (blue) to peak (red). Circles denote 504 recordings sites. Dashed white line denotes the CPC island.
Membrane potentials at selected sites within (1) and outside (2&3) the CPC island are also shown. Electrical stimulus (yellow triangle) yielded action
potential propagation that was significantly slower within the island than in the surrounding cardiomyocytes. Isochrones of electrical propagation
(white lines) are shown at the bottom right of. Note central isochrone crowding due to slow propagation within the CPC island (black dashed line).
doi:10.1371/journal.pone.0011536.g002
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(+) cells over the
entire estimated area of the affected myocardium (<4 mm) and
determined to be 12.762.1% of the initial total number of cells
injected.
We proceeded to examine the differentiation commitment of
the transplanted cells. Large tissue areas surrounding the injury
site co-stained for b-Galactosidase and a-Actinin (Figs. 4a, b)
indicating robust differentiation of the transplanted cells into
cardiomyocytes. At higher magnification, a large number of
individual or clustered CPC-derived cardiomyocytes were detected
incorporated within the host cardiac cell network (Figs. 4c–f).
While the presence of rod cell shape and cross-striations (Fig. 4e)
indicated advanced cell differentiation, smaller size of CPC-
derived cardiomyocytes compared to host cardiomyocytes sug-
gested maturation level inferior to that of the adult cells. The
majority of the b-Gal staining also co-localized with another
cardiac muscle marker Myosin Heavy Chain (MHC, Figs. 4d, f).
In the infarcted region of animals which received CPC injections
several blood vessels comprised of both donor and host cells were
detected (Figs. 4g–j). The bGal
(+) CPCs readily differentiated into
vascular smooth muscle and incorporated in large and small vessels
with bGal
(-) host cells (Figs. 4g, h). The CPCs also differentiated
into endothelial cells in some of the detected blood vessels as
determined by the detection of Vwf and Kdr expression (Figs. 4i, j).
Figure 3. Scar tissue formation and CPC detection. Histological analysis (Mason’s trichrome staining) and immunohistochemical analysis of the
infarcted myocardium demonstrating the extent of scarring (blue) in the myocardium of the three experimental groups at two parallel cross-sections
of the myocardium. Sham surgery and saline injections (a–b). Myocardial infarction and saline injections (c–d). Myocardial infarction and CPC
injections (e–h). Scale bar: 1 mm. High magnification panel pairs show parallel thin cross-sections stained either with Mason’s trichrome stain or with
an antibody against the b-Galactosidase protein which is constitutively expressed in the injected cells (Rosa 26 mouse ESC line). Scar region (i),
Interface between the scar and healthy myocardium (j–l). Healthy myocardium (k). Black arrowheads denote b-Galactosidase
(+) cells within the
myocardium.
doi:10.1371/journal.pone.0011536.g003
Figure 4. Differentiation potential of CPCs in the infarcted myocardium. Low magnification images demonstrating large-scale engraftment
and differentiation of the injected CPCs into the cardiomyocyte cell lineage (a–b). Panels (a) and (b) show parallel thin sections of the infarcted
myocardium. Yellow arrowheads denote the newly formed b-Gal
(+) and a-Actinin
(+) myocardium. High magnification images demonstrating that the
transplanted CPCs primarily differentiated into cardiomyocytes (c–f). Large and small newly formed vessels located within the infarcted region of the
myocardium contain a combination of host and donor cells. Yellow arrowheads denote the b-Gal
(+) donor cells expressing smooth muscle actin (g, h),
Von Willebrand factor (i), and KDR (j).
doi:10.1371/journal.pone.0011536.g004
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(+) uncommitted progenitors were also detected. Taken
together, ESC-derived CPCs committed predominantly to the
cardiac muscle cell fate both when transplanted in the infarcted
heart and when densely seeded in co-culture with rat cardiomyo-
cytes in addition to inducing vascularization.
Since cardiomyocytes in the adult mouse myocardium are
binucleated whereas embryonic stem cell-derived cardiomyocytes
are immature and primarily uninucleated [19] we were able to
delineate differentiation versus cell fusion events by determining
the number of bGal
(+) cardiomyocytes containing a single nucleus.
In our analysis approximately 96% of the identified cells contained
a single nucleus indicating that at least that number of cells were
the result of direct differentiation versus cell fusion.
Electrical and mechanical coupling assessment of CPCs
The capacity of the differentiated CPCs to electrocouple in vivo
with the host myocardium was examined by immunohistochemical
analysis (Figs. 5a–d). The majority of the bGal
(+) cardiomyocytes
which also exhibited Connexin 43 gap-junction staining were
detected at the site of the infarct (Figs. 5a, c). A small number of
the donor cells were detected within the healthy myocardium
(Fig.5b)orattheborderbetweenhealthytissueandinfarct(Fig.5d).
Figure 5. Electromechanical coupling capacity of CPCs. Electrical and mechanical coupling of differentiated CPCs with the host myocardium
and neonatal rat ventricular myocytes. b-Galactosidase
(+) cardiomyocytes form gap junctions as demonstrated by Connexin 43 immunostaining
within the infarcted region (a, c), as well as in the healthy myocardium (b), and at the border area between healthy and infarcted myocardium (d).
CPCs differentiate in vitro into GFP
(+)/a-Actinin
(+) cardiomyocytes (e) and mechanically couple with co-cultured neonatal rat ventricular myocytes as
determined by N-Cadherin detection at the border region between the two cell types (f).
doi:10.1371/journal.pone.0011536.g005
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inter-connections with neonatal rat ventricular cardiomyocytes was
assessed in vitro (Figs. 5e, f). Isolated GFP
(+) CPCs were co-cultured
with NRVMs and subsequently assayed for GFP and N-Cadherin
expression which mediates adhesion in the intercalated discs at the
termini of cardiomyocytes thereby serving as a mechanical anchor
for myofibrils at cell-cell contacts [20]. The GFP
(+) cardiomyocytes,
which were readily distinguishable from the NRVMs, formed N-
Cadherin
(+) intercalated disc cell contracts with the NRVMs.
Determination of cardiac functional output by
echocardiographic evaluation
Myocardial infarction injury produced a time-dependent
ventricular dilatation and left ventricular dysfunction (Fig. 6).
Over a 4-week time span the control group (saline-injected
infracted animals), exhibited a 50% increase (2.8060.2 mm to
4.260.2 mm) of the left ventricular internal diastolic diameter
(LVIDd, Fig. 6a) and an 84% increase (1.6360.2 mm to
3.060.3 mm) of the left ventricular internal systolic diameter
Figure 6. Echocardiographic analysis. Time course of structural and hemodynamic indices obtained using echocardiography in the four studied
groups. The left ventricular size in diastole (a) and systole (b) increased in the saline injected infarct control group while in CPC treated and sham
groups it remained stable over 4 weeks after MI injury (p,0.01). Similarly, the ejection fraction (c) and fractional shortening (d) decreased in the saline
infracted control group while in CPC treated groups remained stable over 4 weeks post infraction (p,0.01). Note that over the course of treatment
neither of 4 indices differed between CPC treated infracted heart and sham groups injected with saline or CPC.
doi:10.1371/journal.pone.0011536.g006
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attenuated the cardiac remodeling, yielding a smaller, 21%,
increase of the LVIDd (2.8860.1 mm to 3.560.18 mm)
and a 53% increase of the LVIDs (1.4760.07 mm to
2.2660.27 mm).
Over the span of 4 weeks the ejection fraction (EF, Fig. 6c)
in the control group (saline-injected infracted animals) de-
creased from 76.866.9% to 38.0610%, while for the CPC-
treated infracted animal group there was a lesser ejection
fraction decrease (79.964% to 63.163%) which was also
comparable to that of the sham groups, thus, indicating
preserved hemodynamic function. Consistent with these results,
fractional shortening (FS) following infarction injury and saline
injection was significantly reduced from 44.2964.4% before
LAD ligation to 26.0865.07% after 4 weeks. In contrast, CPC
injection in the infracted zone preserved the FS (46.0462.32%
to 44.6664.5%) at levels measured prior to the infarction
injury, and similar to the results obtained for the sham groups
(Fig. 6d).
Survival. A total of 55 surgical procedures were performed
with a surgical mortality of 10.9% (Fig. S2). Forty mice finished
the 4 weeks of the study, of which 26 underwent successful
hemodynamic analysis with a pressure-volume catheter.
Determination of cardiac functional output by pressure-
volume analysis
In order to further access the cardiac functional capacity of the four
animal groups we performed Pressure-Volume loop analysis (Fig. 7)
[21]. Consistent with the echocardiographic analysis of ventricular
dilatation, the end diastolic volume (EDV, Fig. 7a) for the saline-
injected infracted animals measured 49.5610.0 ml, as compared to
29.462.9 ml for the CPC-treated infracted animal group. The animals
that underwent sham surgery and received either cells or saline
injections measured 20.161.2 ml and 22.561.9 ml respectively.
Hemodynamic catheterization also allowed the measurement of
the indices of myocardial contractility (Fig. 7b). Peak pressure rise
((dP/dt)max) is a measure of the fastest pressure rise within the left
ventricle during the isovolumetric phase of myocardial contraction
and it can be correlated with the peak acceleration of blood in the
descending aorta through the ventricle. The left ventricular peak
pressure rise ((dP/dt)max) for the control group (saline-injected
infracted animals, 5830.36584.5 mmHg/sec) was lower than that
of the CPC-treated infracted animals (8427.361850.8 mmHg/sec),
which in turn was comparable to the ((dP/dt)max) values measured
for the saline-treated sham animals (10,373.46649.5 mmHg/sec)
but lower than those measured for the cell-treated sham animals
(11,826.061433.6 mmHg/sec).
Figure 7. Pressure-Volume loop analysis. Left ventricular pressure-volume analysis in the four groups 4 weeks post infarction. The CPC treated
group exhibited preservation of ventricular volume in diastole (a) (p,0.01). An improved relaxation constant (Tau-Weiss) is observed in CPC treated
mice (c) (p,0.01). (dP/dt)max (b) and preload recruitable stroke work (PRSW) (d) was improved in the CPC treated group exhibiting preserved
contractility parameters. (e) Sample Pressure-volume loop recordings from individual mice four weeks after myocardial infarction. While the sham
treated mouse has kept its end-diastolic and end-systolic volumes these parameters have increased in MI ones with less maximum pressure, however
the degree of dilatation and remodeling seems increased in the saline treated mouse as compared to the one receiving CPCs.
doi:10.1371/journal.pone.0011536.g007
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which measures the speed of isovolumic relaxation during early
diastole, revealed that the diastolic relaxation of the CPC-treated
infarcted group was faster (7.660.5 msec) than that of the saline-
treated infarcted group (9.161.0 msec) and comparable to the
sham surgery control groups (6.260.3 msec for saline-treated and
6.561.0 msec for CPC-treated). Taken together, the treatment of
infracted hearts with transplanted CPCs resulted in a significant
improvement of both systolic and diastolic indices of cardiac
function compared to untreated, saline injected controls (to levels
comparable to those found in uninfarcted animals).
The measurement of preload recruitable stroke work (PRSW)
relationship, which describes the dependence of the stroke work
on the end diastolic volume, demonstrated a preservation of the
cardiac functional capacity in the cell-treated infarcted group
(Fig. 7d). Specifically, the saline-treated group exhibited signifi-
cantly lower PRSW slope (26.8614.6 mmHg) compared to cell-
treated group (57.3615.3 mmHg), which in turn remained
comparable to both sham groups (Fig. 7d).
Discussion
The main aim of this study was the determination of the
therapeutic capacity of the recently described ESC-derived cardiac
progenitor cells [14] to treat myocardial infarction injury. We first
describe the in vitro differentiation potential of mouse ESC-derived
CPCs. We further demonstrate the capacity of the CPC-derived
cardiomyocytes to form functional gap junctions, propagate action
potentials over a relatively large area, and electrically and
mechanically connect with primary ventricular cardiomyocytes
in culture. Finally, we demonstrate a stable engraftment and
robust cardiomyocyte differentiation of the transplanted CPCs
following myocardial infarction injury, formation of gap junctions
with host cells, as well as significant preservation of cardiac
function in the CPC-treated animals compared to the untreated
group.
A significant aspect of the study is the utilization of a novel cell
progenitor: ESC-derived CPCs selected based on the activity of a
cardiac specific Nkx2-5 [22] enhancer. We recently reported that
the CPCs closely recapitulate the earliest stages of in vivo cardiac
development and are capable of multipotential differentiation into
cell types that contribute to the heart [14]. Success of cell-based
cardiac therapies is dependent not only on the ability of
transplanted cells to differentiate into cardiomyocytes and
functionally integrate with host cells, but also on the adequate
vascularization of the newly formed tissue. The cardiovascular
differentiation potential of the Nkx2-5
(+) CPCs and the relative
ease to obtain large cell numbers represent major advantages for
their potential use as a single therapeutic cell source. Importantly,
since these CPCs are capable of generating both cardiomyocytes
and vascular cells, they may obviate a need for use of additional
vascular cell types [23] or different gene manipulation strategies
[24] to facilitate vascularization of the newly formed cardiac
muscle.
One of the major concerns in using ESCs or their differentiated
progeny for cell-based interventions is the risk of neoplastic tumor
or teratoma [10] formation due to undifferentiated ESCs. Recent
reports describe extensive teratoma formation following injection
of ESCs [25,26]. In one such study, the authors reported tumor
formation in 21% of the mice [26] receiving cells. We have
previously demonstrated that no expression of Nanog or Pou5f1 was
detected following Nkx2-5
(+) CPC derivation and extended culture
in vitro. In contrast, colonies of undifferentiated ESCs and high
expression levels of Nanog and Pou5f1 were found in cultures of the
sorted GFP
(2) cells [14]. Importantly, in this study we observed no
evidence of neoplastic cell growth in the mouse hearts as long as 1
month after cell injections. While these results, along with similar
findings in our previous study [14], strongly suggest that the
narrow differentiation potential of CPCs could be safe for cell-
based therapies, longer grafting times must be studied to further
validate these conclusions.
A major drawback of any allogeneic transplantation therapy is
the immune response which leads to the rejection of transplanted
tissue. In our study we successfully utilized animals with common
genetic background to the donor cells [27] trying to avoid
immunorejection or the need for immunosuppressive therapy.
Even though it has been argued that ESCs and their differentiated
progeny are capable of evading immunorejection [7], two reports
have demonstrated large-scale host immune response against
transplanted ESCs [10,28]. In a clinical setting this issue must be
addressed. Recent studies have proposed several alternatives
including somatic cell nuclear transfer [29], and induced
pluripotent stem cells [30].
The success of any cell-based therapy for myocardial infarction
injury is ultimately judged by the improvement of the heart
function, i.e., decreased heart dilatation and increased cardiac
contractility and output. Based on the optical mapping of electrical
propagation in co-cultures of CPCs and primary ventricular
cardiomyocytes, the observed improvement in cardiac mechanical
indices in treated hearts could be attributed in part to the
functional integration of CPC-derived cardiomyocytes with the
host cells. Of note, however, is the relatively low velocity of
impulse propagation measured within the CPC islands in vitro. This
low conduction velocity was consistent with observed sparse
Connexin 43 expression and possibly contributed by immature (or
mixed from nodal, atrial, and ventricular cells) electrophysiological
phenotype of CPC-derived cardiomyocytes [31]. Conceivably,
more efficient cardiogenic differentiation within the environment
of infracted heart may have yielded higher Connexin 43
expression and maturation of ion currents in engrafted cardiomy-
ocytes resulting in improved functional in vivo integration. In
support, although no systematic studies were done to assess the
arrhythmogenic risk of implanted cells, we observed no difference
in the incidence of sudden cardiac death between cell-treated and
untreated mice. Moreover, we demonstrate in vivo electrical
coupling through gap junction formation of the differentiated
CPCs with the host myocardium.
It is interesting that CPCs plated at high density within neonatal
rat ventricular myocytes primarily differentiated into the cardio-
myocyte lineage, while abundant smooth muscle cells were found
within the sparsely plated islands [32]. On the other hand, CPCs
transplanted in the infarcted hearts primarily differentiated into
cardiomyocytes, indicating that the stiffness of the cell attachment
substrate [33], density of injected cells, and/or other differences
between in vivo and in vitro microenvironments may all significantly
affect their lineage commitment. The systematic studies to
understand the factors that control lineage commitment are
currently underway.
We detected a number of bGal
(+) cardiomyocytes (a-Actinin
(+) or
MYH6
(+)) in the host myocardium suggesting the direct differen-
tiation of the delivered CPCs towards the cardiac muscle lineage.
Admittedly there is a possibility that some of the detected
differentiation events are the result of cell fusion between the host
cardiomyocytes and the CPCs. Recently Kolossov et al. examined
the capacity of both bone marrow derived cells and embryonic
stem cell derived cardiomyocytes to engraft into the infracted
mouse myocardium [34]. Following bone marrow cell transplan-
tation they detected rare fusion events of the delivered cells with
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stem cell-derived cardiomyocytes colocalized in clusters and could
clearly be distinguished from the native cardiomyocytes as a result
of their reduced size, distinct cell shape, and incomplete myofibrils,
which they concluded was strong evidence that the detected cells
were not the result of fusion. Similarly, for the purpose of our study
during an early point analysis of the injected myocardium (day 3
post infraction and cell transplantation, data not shown) we
detected areas with clustered GFP
(+) cells. Although these cells
expressed cardiac markers as determined by immunocytochemis-
try they were small in size and resembled immature cardiomyo-
cytes. Most importantly, one month, post injection 96% of bGal
(+)
cells contained a single nucleus suggesting their direct differenti-
ation into cardiomyocytes versus their fusion with the host cells.
Importantly, through the systematic assessment of cardiac
contractile function, we demonstrated a superior systolic and
diastolic performance of the CPC-treated relative to untreated
hearts. In particular, while the function of untreated hearts was
significantly compromised as early as one week after the infarction
(based on echocardiographic parameters), the functional indices in
CPC-treated hearts remained relatively constant. The preserved
cardiac function was independently confirmed at 4 weeks post-
infarction using pressure-volume analysis. Mechanistically, the
cardiac function was maintained not only due to attenuated
ventricular remodeling including a decrease of scar size and
relatively preserved ventricular volume but more importantly due
to independently preserved contractile function as evidenced from
a higher PRSW slope (a volume independent factor in evaluation
of cardiac function in both systole and diastole).
These findings are consistent with previous reports in
demonstrating that transplantation of ESC-derived cells leads to
the in vivo cardiac improvement following myocardial infarction
[35,36]. It is important to note, however, that the mechanisms
mediating this effect are currently not known [37]. We
acknowledge certain limitations in our work which we plan to
further investigate in the future. In particular we are interested in
addressing the therapeutic mechanism of the CPCs. More
specifically in addition to their direct differentiation capacity into
cardiomyocytes, and vascular cells, the CPCs may induce a
cardioprotective paracrine effect which in turn induces the host
myocardium to regenerate. A genomic expression analysis
performed on the CPCs and reported in our previous work
indicated that Vegf, Igf1, and Notch signaling pathways are active in
the cells both of which have been shown to have pro-vascular and
cardioprotective effects [38,39]. Moreover, in order to be able to
assay in vivo functional integration of the donor cells with the host
myocardium we plan to utilize genetic calcium indicators and two-
photon laser scanning microscopy [40,41].
An additional important determinant of a successful long-term
cell-based cardiac therapy involves the level of cell survival
following direct intramyocardial delivery. Previous studies have
demonstrated a clear correlation between graft size and the level
of functional improvement [42,43]. Thus cell survival determines
graft size and ultimately the level of the therapeutic effect. In
general cell survival depends primarily on the initial number of
cells delivered, the local cell donor density per injection point,
and the status of the tissue in which the cells are being injected
(ischemic/inflamed versus normal) [44]. For this study the cell
survival capacity of the transplanted CPCs was determined to be
12.762.1% which is similar to previous reports utilizing a similar
injury and which determined the cell survival to be between 5–
9% up to a month following initial cell injections [45,46] [47].
Finally, in order to maximize the therapeutic effect of the
delivered CPCs through increased cell survival it may be
necessary to modify the delivery method in order to ensure
decreased apoptosis and localized inflammatory response as well
as prime the cells to cope with the increased stress associated with
the entire process [36].
The recent identification and characterization of adult [48] and
ESC-derived CPCs with multipotential but cardiac tissue-restrict-
ed differentiation capacity has reinvigorated the field of cell-based
cardiac therapies. Taken together, our results clearly demonstrate
the therapeutic value of the ESC-derived CPCs in the infarcted
mouse heart. While potential strategies to control differentiation
fate of CPCs towards blood vessels or cardiac muscle upon
implantation remain to be explored, this study establishes the
foundation and the rationale for the future testing of human
embryonic or induced pluripotent stem cell-derived CPCs for
repair of cardiac infarction.
Materials and Methods
Cell culture and differentiation
Mouse ESCs (D3 [15] and Rosa26 [16] lines) were cultured and
differentiated as previously described [14]. Further detail is
provided in File S1.
DNA plasmids and cell transfection
The previously described [22] cardiac specific enhancer element
(fragment 8) of the mouse Nkx2-5 transcription factor along with
the Hsp68 minimal promoter [49] were excised from the provided
plasmid (XhoI/NcoI) and inserted upstream of the enhanced GFP
gene in the Bluescript vector. This in conjunction with a plasmid
DNA containing the polymerase II promoter at the 59 end the
hygromycin phosphotransferase gene were used to stably transfect
mouse ESCs in the presence of hygromycin. A stable clone from
each cell line was selected for any further experiments.
In vitro CPC differentiation capacity
To assay their differentiation capacity, sorted GFP
(+) CPCs were
re-aggregated for 24 hours in suspension and re-plated on
fibronectin coated tissue culture dishes and further maintained
for seven days in ESC differentiation medium.
Quantitative RT-PCR
Embryoid bodies cultured in hanging droplets or in suspension were
harvested every 24 hours in order to isolate total RNA. For the
quantitative RT-PCR analysis total RNA (2 mg) was reverse
transcribed using random decamers as primers (Ambion, cat.#
57226), and the MMLV-RT enzyme (Invitrogen, 28025-013). Relative
RNA expression levels were measured using quantitative RTPCR.
Detection of the described markers was achieved with FAM/MGB
probes (Applied Biosystems): Nkx2.5 (Mm00657783_m1), Myh6
(Mm00440354_m1), Brachyury (Mm00436877_m1). The instrument
used was the Applied Biosystems ABI Prism 7900HT sequence
detection system and the software for data collection and analysis was
the SDS2.1. An 18S RNA probe (Hs99999901_s1) was used in order
to normalize the data.
Co-culture of CPCs and NRVMs
Fibronectin-coated coverslips and polydimethylsiloxane (PDMS)
rings were used to selectively plate isolated CPCs only in the central
region (5 mm diameter) of the coverslips (low density: 5610
4 cells,
high density: 2.5610
5 cells). Following CPC attachment floating
cells were washed off and the PDMS ring was removed. Isolated
NRVMs were subsequently plated around the CPCs. Washing of
unattached NRVMs within 6–8 hours following plating ensured
minimum NRVM attachment on top of the CPCs.
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immunostaining in CPC-NRVM cocultures
Electrical propagation in CPC/NRVM cocultures was optically
mapped using a bundle of 504 hexagonally arranged optical fibers
(RedShirtImaging) providing a spatial resolution of 750 mmi na
19.5 mm field of view, as previously described [18,50]. Briefly, the
cocultures were incubated for five minutes with a voltage sensitive
dye (di-4 ANEPPS, 16 mM) at room temperature, placed in a
heated recording chamber, perfused with Tyrode’s solution, and
illuminated with a green excitation light (520630 nm). The
recorded red fluorescence (.590 nm) was transferred through the
fiber optic bundle, converted to voltage using photodiodes,
amplified, sampled at 2.4 kHz, and stored on a PC. Before the
onset of pacing, all cocultures were checked for the presence of
spontaneous activity. A XYZ-micropositioned bipolar platinum
electrode was then used to locally stimulate the CPC area in the
center of the monolayer and propagated action potentials were
optically mapped. Electrical stimulation, light exposure, and data
acquisition were synchronized using custom LabView software.
Data analysis was performed using MATLAB as previously
described [18,51]. Activation times were defined as times of
50% upstroke of the action potential and used to construct
isochrone maps. Local conduction velocities were calculated using
the activation time for each optical channel relative to those of
neighboring channels[18].
Following optical mapping analysis the samples were fixed in
4% parafolmaldehyde and stained with antibodies against the GFP
protein (Molecular probes, A21311, A11120), a-Actinin (Sigma,
A7811), Acta2 (Abcam, ab5694), and Connexin 43 (Sigma,
C6219). Secondary antibodies were purchased from Molecular
probes and were conjugates to the fluorochromes Alexa 488, and
Alexa 546. Nuclei were stained with 49,6-diamidino-2-phenylin-
dole (Molecular probes). The samples were imaged with a Nikon
TE2000 and a confocal Zeiss 510 microscope.
Animal Model
A l lr e s e a r c hi n v o l v i n ge x p e r i m e n t a t i o no nv e r t e b r a t e
animals have been specifically approved by Johns Hopkins
Medical Institutions (Animal Protocol # MO0M296). Using a
left anterior thoracotomy, the heart of SVE129 female mice
(8–10 weeks of age) was exposed and LAD was ligated
permanently. For sham surgeries, the needle was passed under
the LAD without ligation. The mice were monitored twice a
day for four weeks. Four experimental groups were established
consisting of animals that underwent LAD ligation and
received phosphate buffered saline injections with (n=15) or
without cells (n=10) and animals that underwent sham
surgeries and also received saline injections with (n=7) or
without cells (n=11). Immediately following infarction injury,
each animal received three injections (10 ml/injection) of saline
or saline with CPCs (0.5–1610
6 cells total) in the boundaries
and the center of the infarcted region. The cells used in these
experiments were GFP
+ CPCs isolated on differentiation day
6. The animals were sacrificed four weeks post-transplantation
and the hearts prepared for immunohistological analysis.
CPC injections
Using a tubing system attached to a standing syringe, we
injected 4–5610
5 cells in three doses (10 ml/injection) directly into
myocardium with a 30-gauge needle. Injections were done
immediately following LAD ligation, into the mid infarct zone
and border-zones. The infarct zone was defined by blanching of
the heart after ligation.
Echocardiography
The analysis was done using a HP/PHILIPS/AGILENT
SONOS 5500. The animals were analyzed prior to surgery (same
day) and at 1, 2, and 4 weeks after it. The procedures were
performed under general anesthesia using isoflurane 1–2%.
Pressure volume loop analysis
4 weeks after the surgery the mice were anesthetized using a
combination of etomidate, morphine and urethane, which were
injected intraperitoneally. Using the right carotid approach a
Millar SPS 839 catheter progressed to the left ventricle. During the
procedure, a diluted 6.25% albumin solution was infused into
jugular vein at a rate of 5 mcl/min. Pressure volume data were
obtained at baseline with closed chest and after opening the thorax
with IVC occlusion. The volume calibration was done using
thoracic aortic flow and hypertonic saline infusion.
Statistical analysis
We obtained average and standard error of mean for all values
and used one way and two way ANOVAs for statistical analysis
(Graph-pad prism 4.03).
Supporting Information
File S1 Cell culture and differentiation, FACS analysis and
sorting, isolation of nrvms, harvesting the hearts and tissue
preparation, immunocytochemistry, statistical analysis.
Found at: doi:10.1371/journal.pone.0011536.s001 (0.06 MB
DOC)
Figure S1 Cardiomyocyte and smooth muscle lineage commit-
ted mouse ESC-derived CPCs functionally electrocouple with
neonatal rat ventricular cardiomyocytes. (a–b) In vitro co-culture of
ESC-derived CPCs with NRVMs. The CPCs were selectively
plated at low density in the center region of the coverslip and
subsequently differentiated into cardiomyocytes and smooth
muscle cells. A confluent layer of NRVMs surrounded the CPCs.
Dashed lines denote the border between the two cell types. Mouse
ESC-derived cardiomyocytes as well as NRVMs stain positive for
a-Actinin (red), whereas only mouse ESC-derived CPCs and
mouse ESC-derived cardiomyocytes express GFP (green). (c–d)
High magnification immunostaining analysis illustrates the
interface of the two cell types demonstrating formation of
Connexin 43 gap junctions. (e) The majority of CPCs plated at
low density differentiated into smooth muscle cells (e, green) with
some cardiomyocyte differentiation (e, red). (f) Sequential
isopotential maps reveal electrical propagation from the central
island of differentiated CPCs to the outside regions containing
primary cardiomyocytes (central island is indicated by dashed
white circle). Color bar shows relative transmembrane potential
normalized from resting (blue) to peak (red) value. The monolayer
was electrically stimulated by a point electrode in the center,
indicated by the yellow pulse sign in 0 ms frame. The timing index
has been set relative to the stimulus pulse (indicated by the yellow
triangle on membrane potential traces). Membrane potential
traces are from three channels (channel 1 in the central island of
cardiac progenitor cells and channels 2 and 3 in the outside region
with cardiac cells). Note that electrical propagation was very slow
inside the central island due to predominance of CPC-derived
smooth muscle cells and significantly accelerated after exiting to
the outside cardiomyocyte region.
Found at: doi:10.1371/journal.pone.0011536.s002 (3.21 MB TIF)
Figure S2 Kaplan-Meyer survival graph showing the four study
arms during the four weeks after myocardial infarction. Logrank
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animal deaths in the four experimental groups.
Found at: doi:10.1371/journal.pone.0011536.s003 (1.25 MB TIF)
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